Literature DB >> 6913608

Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae.

C Mold, H Gewurz.   

Abstract

C-reactive protein (CRP) is an acute phase serum protein found associated with damaged tissue at sites of inflammation. CRP bound to multivalent phosphocholine-containing or polycationic ligands activates C by the classical pathway. We have previously described liposomes of a particular lipid composition that are able both to activate the alternative pathway of C and to bind CRP. In addition many strains of Streptococcus pneumoniae activate the alternative pathway. We have shown CRP binding to these bacteria as well. Because antibody to an activating surface in many cases enhances alternative pathway activation, we tested CRP for a similar function in these systems. Our results indicate that, in contrast to antibody, CRP inhibits alternative pathway activation. This inhibition by CRP is apparently restricted to surfaces that bind CRP. Thus, CRP binding to membrane or bacterial surfaces can convert them from alternative pathway activation to classical pathway activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6913608

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Studies on the interactions between C-reactive protein and complement proteins.

Authors:  Adrienn Bíró; Zita Rovó; Diana Papp; László Cervenak; Lilian Varga; George Füst; Nicole M Thielens; Gérard J Arlaud; Zoltán Prohászka
Journal:  Immunology       Date:  2007-01-18       Impact factor: 7.397

2.  Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP).

Authors:  C Suankratay; C Mold; Y Zhang; L A Potempa; T F Lint; H Gewurz
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

3.  Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella.

Authors:  J E Schweinle; R A Ezekowitz; A J Tenner; M Kuhlman; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 4.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

5.  Calcium-dependent binding of rabbit C-reactive protein to supported lipid monolayers containing exposed phosphorylcholine group.

Authors:  S F Sui; Y T Sun; L Z Mi
Journal:  Biophys J       Date:  1999-01       Impact factor: 4.033

6.  Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

7.  Relationships between alternative complement pathway activation, C-reactive protein, and pneumococcal infection.

Authors:  R A Rabinovitch; S M Koethe; J H Kalbfleisch; L C Preheim; M W Rytel
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

8.  C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.

Authors:  D Gershov; S Kim; N Brot; K B Elkon
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 9.  Structure-Function Relationships of C-Reactive Protein in Bacterial Infection.

Authors:  Donald N Ngwa; Alok Agrawal
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

Review 10.  An overview on human serum lectins.

Authors:  S Beulaja Manikandan; R Manikandan; M Arumugam; P Mullainadhan
Journal:  Heliyon       Date:  2020-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.